Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1

Abstract

Introduction. Aliskiren is the first in a new class of direct renin inhibitors to be approved for the treatment of hypertension.

Patients and methods. In this double-blind, multicentre trial, 694 patients with hypertension (mean sitting diastolic blood pressure [BP] ≥ 95 and < 110 mmHg) were randomised to once-daily aliskiren 150 mg (n=231), atenolol 50 mg (n=231) or the combination (150/50 mg; n=232) for six weeks, followed by a further six weeks on double the initial doses of aliskiren and atenolol. Efficacy (reduction from baseline in mean sitting systolic and diastolic BP) and tolerability of study treatments were assessed; plasma renin activity (PRA) was measured in a subset of patients.

Results. At Week 12 endpoint, aliskiren, atenolol and aliskiren/atenolol lowered systolic and diastolic BP from baseline by 14.3/11.3, 14.3/13.7 and 17.3/14.1 mmHg, respectively. Systolic BP reductions with aliskiren/atenolol were significantly greater than those with aliskiren (p=0.039) or atenolol (p=0.034) alone, and diastolic BP reductions were greater than with aliskiren alone (p<0.001). Diastolic BP changes were larger with atenolol than with aliskiren (p=0.003, correlating with the large reductions in pulse rate (> 10 bpm) observed with atenolol. Aliskiren, atenolol and aliskiren/atenolol reduced geometric mean PRA from baseline by 65%, 52% and 61%, respectively. In patients with moderate or high baseline PRA (≥ 0.65 ng/ml/hour), PRA was reduced to low levels (< 0.65 ng/ml/hour) at Week 12 endpoint in a greater proportion of patients receiving aliskiren (11/15 patients, 73.3%) or aliskiren/atenolol (18/23, 78.3%) than with atenolol (10/21, 47.6%). Aliskiren treatment was associated with numerically lower rates of adverse events and discontinuations due to adverse events compared with atenolol or combination treatment, and unlike atenolol was not associated with bradycardia.

Conclusions. Direct renin inhibition with aliskiren may be an appropriate substitute for beta-blocker treatment in patients with uncomplicated hypertension. Aliskiren also represents an attractive option for dual therapy with atenolol to improve systolic BP/pulse pressure reductions and BP control with maintained tolerability compared with atenolol alone.

Keywords

aliskiren beta-blocker plasma renin activity pulse pressure renin-angiotensin system

Get full access to this article

View all access options for this article.

References

Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade . J Hypertens Suppl 2005;23:S9-S17.

Wood JM , Maibaum J. , Rahuel J. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.

Nussberger J. , Wuerzner G. , Jensen C. , Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril . Hypertension 2002;39:E1-E8.

Pool JL , Schmieder RE , Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20.

Uresin Y. , Taylor A. , Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension . J Renin Angiotensin Aldosterone Syst 2007 ; 8: 190-8.

Villamil A. , Chrysant SG , Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26.

Kilo C. , Taylor A. , Tschope D. , Ibram G. , Fang H. , Prescott MF Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 2006;27(suppl):118-19P789.

Yarows SA , Oparil S. , Patel S. , Zhang J. , Fang H. , Satlin A. Suppression of the renin system with the oral direct renin inhibitor aliskiren alone and in combination with valsartan in patients with hypertension. J Hypertens 2007; 25(suppl):S257-S258

Nielsen I. , Steiness E. , Hesse B. Acute and long-term salt depletion and beta-blockade: plasma renin activity response and its relation to blood pressure reduction in long-term treatment . Acta Med Scand 1978;203:415-18.

10.

Bravo EL , Tarazi RC , Dustan HP , Lewis JW Dissociation between renin and arterial pressure responses to beta-adrenergic blockade in human essential hypertension. Circ Res 1975;36:241-7.

11.

Blumenfeld JD , Sealey JE , Mann SJ et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.

12.

Williams B. , Poulter NR , Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.

13.

Dahlof B. , Sever PS , Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.

14.

Lindholm LH , Carlberg B. , Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.

15.

Khan N. , McAlister FA Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174:1737-42.

16.

Wiysonge C. , Bradley H. , Mayosi B. et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;CD002003.

17.

National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. 2006;http://www.nice.org.uk/CG034 accessed 28th March 2007.

18.

Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006;7:61-3.

19.

Mancia G. , De Backer G. , Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.

20.

Alderman MH , Cohen HW , Sealey JE , Laragh JH Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004;17:1-7.

21.

Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982;248:2004-11.

22.

Psaty BM , Furberg CD , Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001;161:1183-92.

23.

Vaccarino V. , Holford TR , Krumholz HM Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000;36:130-8.

24.

Franklin SS , Khan SA , Wong ND , Larson MG , Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100: 354-60.

25.

Blacher J. , Staessen JA , Girerd X. et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.

26.

Hirata K. , Vlachopoulos C. , Adji A. , O'Rourke MF

Benefits from angiotensin-converting enzyme inhibitor `beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?

J Hypertens 2005;23:551-6.

27.

Chen CH , Ting CT , Lin SJ et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995 ;25:1034-41.

28.

Williams B. , Lacy PS , Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.

29.

Buhler FR , Laragh JH , Baer L. , Vaughan ED Jr , Brunner HR Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972;287:1209-14.

30.

Nilsson OR , Karlberg BE , Ohlsson O. , Thulin T. , Tolagen K. Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. Acta Med Scand 1979;206:303-8.

31.

Michelakis AM , McAllister RG The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 1972;34:386-94.

32.

Bravo EL , Tarazi RC , Dustan HP On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol. J Lab Clin Med 1974;83:119-28.

33.

Lijnen P. , Fagard R. , Staessen J. , Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981;12:387-92.

34.

Batenburg WW , de Bruin RJ , van Gool JM et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28:1151-7.

35.

Menard J. , Guyene TT , Peyrard S. , Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006;24:529-34.

36.

Schalekamp MA , Derkx FH , Deinum J. , Danser AJ Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens 2008;26:928-37.

37.

Mason JM , Dickinson HO , Nicolson DJ , Campbell F. , Ford GA , Williams B. The diabetogenic potential of thiazidetype diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005;23:1777-81.

38.

Gillespie EL , White CM , Kardas M. , Lindberg M. , Coleman CI The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes . Diabetes Care 2005;28:2261-6.

39.

Weycker D. , Edelsberg J. , Vincze G. et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007;21:374-80.

40.

Oh BH , Mitchell J. , Herron JR , Chung J. , Khan M. , Keefe DL Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49: 1157-63.

41.

Gradman AH , Schmieder RE , Lins RL , Nussberger J. , Chiang Y. , Bedigian MP Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients . Circulation 2005;111:1012-18.

42.

Sica D. , Gradman AH , Lederballe O. , Meyers M. , Cai J. , Keefe DL Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006;27(suppl):121P797.

43.

Law MR , Wald NJ , Morris JK , Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003 ;326: 1427-34.